Last reviewed · How we verify
NCT01893788: EARTH
Eplerenone and Aliskiren Research Targeting Hypertensive Patients With Left Ventricular Hypertrophy
Phase 4 trial testing Aliskiren in Hypertensive Left Ventricular Hypertrophy in 100 participants. Status unknown.
1 March 2016
Quick facts
| Lead sponsor | Nagoya University |
|---|---|
| Phase | Phase 4 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 100 |
| Start date | 1 April 2013 |
| Primary completion | 1 March 2016 |
| Sites | 1 location across Japan |
Drugs / interventions tested
- Aliskiren (ALISKIREN) — full drug profile →
- Eplerenone (EPLERENONE) — full drug profile →
Conditions studied
- Hypertensive Left Ventricular Hypertrophy — all drugs for Hypertensive Left Ventricular Hypertrophy →
Sponsor
Nagoya University
Who can join
Adults 20 to 80, any sex, with Hypertensive Left Ventricular Hypertrophy. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
reduction of left ventricular hypertrophy measured by magnetic resonance imaging
Time frame: 12 month
To compare the 12 month left ventricular mass or left ventricular mass and index measured by magnetic resonance imaging with baseline.
Sponsor's own description
The primary objective of this study is to determine which treatment will be more effective to reduce left ventricular mass in hypertensive patients with left ventricular hypertrophy comparing aliskiren and eplerenone.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT01893788
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Aliskiren
Trials testing the same drug.
- NCT06718062 — Non-Inferiority Study of Aliskiren vs Losartan in the Treatment of Hypertension With Hyperuricemia · Phase 4 · completed
- NCT00667719 — A Long Term Safety Study to Test the Combination of Aliskiren/ Amlodipine / Hydrochlorothiazide in Participants With Ess · Phase 3 · completed
Other Nagoya University trials
Trials by the same sponsor.
- NCT06983210 — Clinical Trial of AM80 in Combination With Gemcitabine, Cisplatin, and Nivolumab in Patients With Urothelial Carcinoma · Phase 2 · recruiting
- NCT06481358 — Deep Learning-based Artificial Intelligence for the Diagnosis of Small Bowel Obstruction · active not recruiting
- NCT05064618 — Investigator-initiated Clinical Trial of MIKE-1 · Phase 1, PHASE2 · recruiting
- NCT04342325 — The Clinical Trial of ADR-001 for IgA Nephropathy · Phase 1 · completed
- NCT04261335 — The Clinical Trial of CL2020 Cells for Neonatal Hypoxic Ischemic Encephalopathy · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01893788 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Nagoya University
- Last refreshed: 18 July 2013
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01893788.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing